Scarica l'app Stockscreener
4.16
5.85%
0.23
Precedente Chiudi:
$3.93
Aprire:
$3.92
Volume 24 ore:
732.45K
Relative Volume:
1.11
Capitalizzazione di mercato:
$245.15M
Reddito:
$192.64M
Utile/perdita netta:
$2.51M
Rapporto P/E:
79.39
EPS:
0.0524
Flusso di cassa netto:
$12.42M
1 W Prestazione:
+5.32%
1M Prestazione:
-4.81%
6M Prestazione:
-16.80%
1 anno Prestazione:
-25.45%
Intervallo 1D:
$3.89
$4.2395
Intervallo di 1 settimana:
$3.8092
$4.2395
Portata 52W:
$3.8092
$6.75
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Nome
Vanda Pharmaceuticals Inc
Settore
Industria
Telefono
202-734-3400
Indirizzo
2200 PENNSYLVANIA AVE NW, WASHINGTON
Confronta VNDA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.16 | 232.79M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-31 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Downgrade | Jefferies | Buy → Hold |
| 2021-05-12 | Iniziato | BofA Securities | Buy |
| 2021-01-14 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-03-16 | Downgrade | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-07 | Downgrade | Citigroup | Buy → Neutral |
| 2019-08-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-07-25 | Downgrade | Stifel | Buy → Hold |
| 2018-12-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Reiterato | Jefferies | Buy |
| 2018-11-08 | Ripresa | Jefferies | Buy |
| 2018-09-21 | Ripresa | Oppenheimer | Outperform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2017-09-14 | Reiterato | Piper Jaffray | Overweight |
| 2017-06-27 | Ripresa | Piper Jaffray | Overweight |
| 2017-05-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-04-12 | Iniziato | Oppenheimer | Outperform |
| 2016-11-09 | Iniziato | Aegis Capital | Buy |
| 2016-10-06 | Ripresa | Jefferies | Buy |
Mostra tutto
Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 | VNDA Stock News - GuruFocus
Vanda Pharmaceuticals Sets Key Investor Meetings at Major Neuro & Ophthalmology Conference Next Week - Stock Titan
Mystics tap D.C.'s Vanda Pharmaceuticals as new jersey sponsor - The Business Journals
Monumental Sports & Entertainment Announces Vanda Pharmaceuticals Inc. as Official Partner and Jersey Patch Partner for the Washington Mystics - Monumental Sports
Vanda Pharmaceuticals (VNDA) Receives Overweight Rating from Can - GuruFocus
Vanda Pharmaceuticals (VNDA) Projected to Transform with Overwei - GuruFocus
Vanda Pharmaceuticals assumed with an Overweight at Cantor Fitzgerald - TipRanks
Vanda Receives Positive CHMP Opinion for HETLIOZ® (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder in the European Union | Libero Quotidiano.it - Libero Quotidiano
Vanda pharmaceuticals outlines $210M-$250M revenue target for 2025 amid product launches - MSN
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2025 Earnings Call Transcript - Insider Monkey
Vanda Pharmaceuticals’ Earnings Call: Growth Amid Challenges - TipRanks
Vanda Pharmaceuticals Inc (VNDA) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Rising ... - Yahoo Finance
Vanda: Q1 Earnings Snapshot - MySA
Vanda Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Vanda Pharmaceuticals Q1 2025 Earnings: EPS Loss of $0.50 Beats - GuruFocus
Earnings call transcript: Vanda Pharmaceuticals misses Q1 2025 forecasts - Investing.com
Capitals Announce Game 3 Watch Party at The Wharf as Part of Additional Playoffs Initiatives Presented by Vanda Pharmaceuticals Inc. - NHL.com
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Vanda Pharmaceuticals Q1 2025 Earnings: EPS Loss of $0.50 Beats Estimate, Revenue Surpasses Forecast at $50 Million - GuruFocus
Vanda Pharmaceuticals (VNDA) Reports Strong Q1 Revenue and Expands Product Pipeline | VNDA Stock News - GuruFocus
Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results - StreetInsider
HC Wainwright & Co. Reiterates Buy Rating on Vanda Pharmaceutica - GuruFocus
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial R - GuruFocus
A Glimpse of Vanda Pharma's Earnings Potential - Nasdaq
3 Penny Stocks Under $300M Market Cap To Consider - simplywall.st
Vanda Pharmaceuticals Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView
Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma - Barchart.com
Drugmaker Vanda Announces Bysanti NDA Filing - marketscreener.com
FDA Begins Review Process on Vanda Pharmaceuticals' (VNDA) Drug - GuruFocus
FDA accepts Vanda’s new antipsychotic drug for review By Investing.com - Investing.com India
FDA accepts Vanda’s new antipsychotic drug for review - Investing.com
Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026 | VNDA Stock News - GuruFocus
Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026 - PR Newswire
FDA Sets 2026 Decision Date for Vanda's New Mental Health Drug with 20+ Year Patent Life - Stock Titan
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 - The Malaysian Reserve
Press Release Distribution & PR Platform - ACCESS Newswire
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 | VNDA Stock News - GuruFocus
Vanda Pharmaceuticals Earnings Alert: Key Q1 2025 Financial Results Drop May 7 After Market Close - Stock Titan
Vanda Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
FDA’s job cuts paint mixed picture for drugmakers’ R&D plans - Yahoo Finance
Halozyme sues Merck; FDA blames cuts for Vanda delay - BioPharma Dive
FDA delays Vanda Pharmaceuticals drug hearing By Investing.com - Investing.com India
FDA delays Vanda Pharmaceuticals drug hearing - Investing.com Australia
Vanda claims FDA 'unlawfully' delays hearing request on tradipitant decision - MSN
Vanda Pharmaceuticals Inc Azioni (VNDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):